abstral 300microgram sublingual tablets
kyowa kirin international uk newco ltd - fentanyl citrate - sublingual tablet - 300microgram
abstral 200microgram sublingual tablets
kyowa kirin international uk newco ltd - fentanyl citrate - sublingual tablet - 200microgram
subutex 8mg sublingual tablets
waymade healthcare plc - buprenorphine hydrochloride - sublingual tablet - 8mg
subutex 8mg sublingual tablets
dowelhurst ltd - buprenorphine hydrochloride - sublingual tablet - 8mg
subutex 8mg sublingual tablets
mawdsley-brooks & company ltd - buprenorphine hydrochloride - sublingual tablet - 8mg
subutex 8mg sublingual tablets
necessity supplies ltd - buprenorphine hydrochloride - sublingual tablet - 8mg
natzon 0.4mg sublingual tablets
morningside healthcare ltd - buprenorphine hydrochloride - sublingual tablet - 400microgram
silcap 50 sildenafil (as citrate) 50 mg capsule blister pack
ix biopharma pty ltd - sildenafil citrate, quantity: 70.24 mg (equivalent: sildenafil, qty 50 mg) - capsule - excipient ingredients: magnesium stearate; croscarmellose sodium; sunset yellow fcf; lactose monohydrate; tartrazine; titanium dioxide; gelatin; silicon dioxide; sodium lauryl sulfate - sildenafil is indicated for the treatment of erectile dysfunction in adult males. ,sildenafil is not indicated for use by women.
silcap 25 sildenafil (as citrate) 25 mg capsule blister
ix biopharma pty ltd - sildenafil citrate, quantity: 35.12 mg (equivalent: sildenafil, qty 25 mg) - capsule - excipient ingredients: magnesium stearate; lactose monohydrate; croscarmellose sodium; titanium dioxide; gelatin; silicon dioxide; sodium lauryl sulfate - sildenafil is indicated for the treatment of erectile dysfunction in adult males. ,sildenafil is not indicated for use by women.
itranox itraconazole 100 mg capsule blister pack
arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itranox is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.